Funding for this research was provided by:
Innovative Medicines Initiative (115966)
Received: 11 November 2019
Accepted: 1 June 2020
First Online: 19 June 2020
Ethics approval and consent to participate
: Not applicable. In accordance with Dutch law, this study is not subject to the Medical Research Involving Human Subjects Act 1998 (Wet Medisch-Wetenschappelijk Onderzoek Met Mensen (WMO)) because 1. It does <i>not</i> concern medical scientific research and 2. Participants are <i>not</i> subject to procedures or are required to follow rules of behaviour. Therefore, this study is not subject to review by an accredited Medical Research Ethics Committee (MREC) or Central Committee on Research Involving Human Subjects (CCMO).
: Not applicable.
: BL declares the following competing interests: employee of Janssen Research and Development, LLC; and stockholder in Johnson & Johnson and in a portfolio that at times includes other pharmaceutical and health care-related companies. JJ declares the following competing interests: employee of Sanofi, a global biopharmaceutical company focused on human health; and ownership of shares in Sanofi and in investment portfolio which at times includes other pharmaceutical and health care-related companies. VP is an employee of Sanofi and stockholder in Sanofi. RD is an employee of Janssen Research and Development, LLC and stockholder in Johnson & Johnson. CAP is an employee of Merck & Co, Inc. (Kenilworth, NJ, USA), and is a stockholder in this company. All other authors have no competing interests to declare.